SynthesisFrontiers in medicine2026
Chemoprophylaxis effect of EGCG on various digestive system diseases: a systematic review and meta-analysis.
Synthesis in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Epigallocatechin-3-gallate (EGCG) constitutes the main component of tea polyphenols found in tea leaves and has been found to have a positive therapeutic effect on various digestive system diseases. However, no systematic review has been conducted on the research progress and mechanisms of EGCG in relation to digestive system diseases, an its toxicity. Methods: We conducted a comprehensive literature search for preclinical studies from the inception of each database to 28th September 2025, including Embase, PubMed, Web of Science, China National Knowledge Infrastructure and Veipu Information. These studies were manually screened based on predefined criteria. A comprehensive literature review and meta-analysis were then performed in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Results: A total of 74 animal studies were initially included. Following screening, 63 studies (involving 738 animals) met the inclusion criteria for the meta-analysis. EGCG's animal experiments in digestive system diseases primarily focus on tongue squamous cancer, colorectal cancer, liver cancer, ulcerative colitis, gastric cancer, and functional gastrointestinal disorders. EGCG also has positive effects on pancreatic cancer, radiation enteritis, hepatitis B, oral cancer, esophageal cancer, radiation-induced esophagitis, hepatitis C, acute pancreatitis, fatty liver, and cancer prevention. The potential common pathways include VEGF, EGFR, Notch, Bax/Caspase, Nrf2/UGTIA10, JAK/STAT, NF-κB, IGF/IGF-IR, Caspase-1, HIF-1α/VEGF, TGFβ/p-ERK/p-Smad1/2 and M1/M2 cell polarization. EGCG suppresses cell proliferation through the induction of apoptosis; however, its underlying mechanisms warrant further investigation. Administration of high-dose EGCG alone can induce hepatotoxicity, an effect that is exacerbated under inflammatory conditions. In the context of diabetes, EGCG may also lead to nephrotoxicity. It should be noted that these toxic doses substantially exceed the levels typically attained through normal dietary consumption of tea. The mechanisms responsible for EGCG-mediated toxicity remain to be fully elucidated. Conclusion:
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.